{
    "root": "bf20f184-d291-47a1-bb01-8dd5846132e4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Prolia",
    "value": "20250428",
    "ingredients": [
        {
            "name": "DENOSUMAB",
            "code": "4EQZ6YO2HI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06643"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "prolia rank ligand ( rankl ) inhibitor indicated treatment : postmenopausal women osteoporosis high risk fracture ( 1.1 ) increase bone mass men osteoporosis high risk fracture ( 1.2 ) glucocorticoid-induced osteoporosis men women high risk fracture ( 1.3 ) increase bone mass men high risk fracture receiving androgen deprivation therapy nonmetastatic prostate cancer ( 1.4 ) increase bone mass women high risk fracture receiving adjuvant aromatase inhibitor therapy breast cancer ( 1.5 )",
        "doid_entities": [
            {
                "text": "osteoporosis (DOID:11476)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11476"
            },
            {
                "text": "glucocorticoid-induced osteoporosis (DOID:0060343)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060343"
            },
            {
                "text": "prostate cancer (DOID:10283)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10283"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "pregnancy must ruled prior prolia . ( 2.1 ) initiating prolia patients advanced chronic kidney disease , including dialysis patients , evaluate presence chronic kidney disease mineral bone disorder intact parathyroid hormone , serum calcium , 25 ( oh ) vitamin , 1,25 ( oh ) 2 vitamin d. ( 2.2 , 5.1 , 8.6 ) prolia administered healthcare professional . ( 2.3 ) administer 60 mg every 6 months subcutaneous injection upper arm , upper thigh , abdomen . ( 2.3 ) instruct patients take calcium 1000 mg daily least 400 iu vitamin daily . ( 2.3 )",
        "doid_entities": [
            {
                "text": "chronic kidney disease (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            },
            {
                "text": "kidney disease (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic kidney disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_133"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "prolia contraindicated : patients hypocalcemia : pre-existing hypocalcemia must corrected prior initiating therapy prolia [ ( 5.1 ) ] . pregnant women : prolia may cause fetal harm administered pregnant woman . women reproductive potential , pregnancy testing performed prior initiating treatment prolia [ ( 8.1 ) ] . patients hypersensitivity prolia : prolia contraindicated patients history systemic hypersensitivity component product . included anaphylaxis , facial swelling , urticaria [ ( 5.3 ) , ( 6.2 ) ] .",
    "indications_original": "Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )",
    "contraindications_original": "Pregnancy must be ruled out prior to administration of Prolia. ( 2.1 ) Before initiating Prolia in patients with advanced chronic kidney disease, including dialysis patients, evaluate for the presence of chronic kidney disease mineral and bone disorder with intact parathyroid hormone, serum calcium, 25(OH) vitamin D, and 1,25(OH) 2 vitamin D. ( 2.2 , 5.1 , 8.6 ) Prolia should be administered by a healthcare professional. ( 2.3 ) Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen. ( 2.3 ) Instruct patients to take calcium 1000 mg daily and at least 400 IU vitamin D daily. ( 2.3 )",
    "adverseReactions_original": "Prolia is contraindicated in:\n                  \n                     Patients with hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia [see Warnings and Precautions (5.1)].\n                     Pregnant women: Prolia may cause fetal harm when administered to a pregnant woman.  In women of reproductive potential, pregnancy testing should be performed prior to initiating treatment with Prolia [see Use in Specific Populations (8.1)].\n                     Patients with hypersensitivity to Prolia: Prolia is contraindicated in patients with a history of systemic hypersensitivity to any component of the product.  Reactions have included anaphylaxis, facial swelling, and urticaria [see Warnings and Precautions (5.3),  Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Prolia",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13438"
        }
    ]
}